SOP for compliance with Indian GCP SAE – Clinical Research Made Simple https://www.clinicalstudies.in Trusted Resource for Clinical Trials, Protocols & Progress Tue, 21 Oct 2025 02:03:10 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.1 SOP for SAE Compensation Assessment, Payment, and Reporting Timelines https://www.clinicalstudies.in/sop-for-sae-compensation-assessment-payment-and-reporting-timelines/ Tue, 21 Oct 2025 02:03:10 +0000 ]]> https://www.clinicalstudies.in/?p=7085 Read More “SOP for SAE Compensation Assessment, Payment, and Reporting Timelines” »

]]>
SOP for SAE Compensation Assessment, Payment, and Reporting Timelines

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-sae-compensation-assessment-payment-and-reporting-timelines”
},
“headline”: “SOP for SAE Compensation Assessment, Payment, and Reporting Timelines”,
“description”: “This SOP outlines procedures for assessing, compensating, and reporting Serious Adverse Events (SAEs) in Indian clinical trials. It ensures compliance with DCGI/CDSCO guidelines, NDCTR 2019, and subject rights protection, covering assessment, timelines, payment, and reporting obligations.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for SAE Compensation Assessment, Payment, and Reporting Timelines

SOP No. CR/OPS/145/2025
Supersedes NA
Page No. X of Y
Issue Date 26/08/2025
Effective Date 01/09/2025
Review Date 01/09/2026

Purpose

The purpose of this SOP is to define procedures for the assessment, payment, and reporting of Serious Adverse Event (SAE) compensation in clinical trials conducted in India. It ensures compliance with the Drugs Controller General of India (DCGI), Central Drugs Standard Control Organization (CDSCO), and New Drugs and Clinical Trials Rules (NDCTR), 2019. The SOP safeguards participant rights and ensures transparency in compensation timelines.

Scope

This SOP applies to sponsors, CROs, investigators, and ethics committees involved in clinical trials conducted in India where SAEs result in trial-related injury or death. It covers SAE assessment, compensation calculation, payment timelines, reporting to DCGI and ethics committees, and documentation.

Responsibilities

  • Sponsor: Assesses SAE compensation liability, arranges for timely payment, and reports to DCGI/EC.
  • Investigator: Reports SAEs within 24 hours, provides required medical documentation, and supports compensation process.
  • CRO: Coordinates assessment and reporting on behalf of sponsor.
  • EC: Reviews SAE assessment reports and approves compensation decisions.
  • QA: Audits SAE reporting and payment records for compliance.

Accountability

The Sponsor’s Medical and Regulatory Affairs Head is accountable for timely SAE compensation assessment, disbursement, and regulatory reporting compliance.

Procedure

1. SAE Reporting
1.1 Investigator reports SAE to sponsor, EC, and DCGI within 24 hours.
1.2 Document in SAE Initial Report Log (Annexure-1).

2. Causality Assessment
2.1 Sponsor’s Independent Expert Committee conducts causality assessment within 30 days.
2.2 Record decision in SAE Causality Assessment Log (Annexure-2).

3. Compensation Calculation
3.1 Compensation calculated as per DCGI formula (NDCTR, 2019).
3.2 Record calculation details in Compensation Calculation Log (Annexure-3).

4. EC Review
4.1 Submit assessment and proposed compensation to Ethics Committee for approval.
4.2 Document review outcome in EC Review Log (Annexure-4).

5. Payment Execution
5.1 Disburse compensation within 30 days of EC/DCGI approval.
5.2 Record transaction in Compensation Payment Log (Annexure-5).

6. Reporting Timelines
6.1 Final compensation report submitted to DCGI and EC within 45 days of SAE reporting.
6.2 Archive all reports in TMF and ISF.

Abbreviations

  • SOP: Standard Operating Procedure
  • SAE: Serious Adverse Event
  • EC: Ethics Committee
  • DCGI: Drugs Controller General of India
  • CDSCO: Central Drugs Standard Control Organization
  • CRO: Contract Research Organization
  • QA: Quality Assurance
  • TMF: Trial Master File
  • ISF: Investigator Site File
  • NDCTR: New Drugs and Clinical Trials Rules

Documents

  1. SAE Initial Report Log (Annexure-1)
  2. SAE Causality Assessment Log (Annexure-2)
  3. Compensation Calculation Log (Annexure-3)
  4. EC Review Log (Annexure-4)
  5. Compensation Payment Log (Annexure-5)

References

Version: 1.0

Approval Section

Prepared By Ravi Kumar, Medical Affairs Specialist
Checked By Sunita Reddy, QA Officer
Approved By Dr. Anil Sharma, Head Clinical Operations

Annexures

Annexure-1: SAE Initial Report Log

Date Subject ID SAE Description Reported By Status
01/09/2025 SUB-201 Severe Allergic Reaction Dr. Mehta Notified

Annexure-2: SAE Causality Assessment Log

Date Subject ID SAE Assessment Result Reviewed By
10/09/2025 SUB-201 Severe Allergic Reaction Related Expert Committee

Annexure-3: Compensation Calculation Log

Date Subject ID Compensation Amount Calculated By Status
15/09/2025 SUB-201 ₹7,50,000 Medical Affairs Proposed

Annexure-4: EC Review Log

Date Protocol ID EC Decision Reviewed By Status
20/09/2025 CTA-2025-02 Approved EC Chairperson Completed

Annexure-5: Compensation Payment Log

Date Subject ID Compensation Paid Paid By Status
25/09/2025 SUB-201 ₹7,50,000 Sponsor Disbursed

Revision History

Revision Date Revision No. Revision Details Reason for Revision Approved By
26/08/2025 00 Initial version New SOP creation Head Clinical Operations

For more SOPs visit: Pharma SOP

]]>